These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33012191)

  • 21. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization.
    Karche NP; Bhonde M; Sinha N; Jana G; Kukreja G; Kurhade SP; Jagdale AR; Tilekar AR; Hajare AK; Jadhav GR; Gupta NR; Limaye R; Khedkar N; Thube BR; Shaikh JS; Rao Irlapati N; Phukan S; Gole G; Bommakanti A; Khanwalkar H; Pawar Y; Kale R; Kumar R; Gupta R; Praveen Kumar VR; Wahid S; Francis A; Bhat T; Kamble N; Patil V; Nigade PB; Modi D; Pawar S; Naidu S; Volam H; Pagdala V; Mallurwar S; Goyal H; Bora P; Ahirrao P; Singh M; Kamalakannan P; Naik KR; Kumar P; Powar RG; Shankar RB; Bernstein PR; Gundu J; Nemmani K; Narasimham L; George KS; Sharma S; Bakhle D; Kamboj RK; Palle VP
    Bioorg Med Chem; 2020 Dec; 28(24):115819. PubMed ID: 33120078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis of Some Benzimidazole-derived Molecules and their Effects on PARP-1 Activity and MDA-MB-231, MDA-MB-436, MDA-MB-468 Breast Cancer Cell Viability.
    Gurkan-Alp AS; Alp M; Karabay AZ; Koc A; Buyukbingol E
    Anticancer Agents Med Chem; 2020; 20(14):1728-1738. PubMed ID: 32357823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and biological evaluation of 4-amidobenzimidazole acridine derivatives as dual PARP and Topo inhibitors for cancer therapy.
    Yuan Z; Chen S; Chen C; Chen J; Chen C; Dai Q; Gao C; Jiang Y
    Eur J Med Chem; 2017 Sep; 138():1135-1146. PubMed ID: 28763648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2.
    Yu J; Luo L; Hu T; Cui Y; Sun X; Gou W; Hou W; Li Y; Sun T
    Eur J Med Chem; 2022 Jan; 227():113898. PubMed ID: 34656898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors.
    Xiang HY; Chen JY; Huan XJ; Chen Y; Gao ZB; Ding J; Miao ZH; Yang CH
    Bioorg Med Chem Lett; 2021 Jan; 31():127710. PubMed ID: 33246105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High affinity and low PARP-trapping benzimidazole derivatives as a potential warhead for PARP1 degraders.
    Peng X; Li Y; Qu J; Jiang L; Wu K; Liu D; Chen Y; Peng J; Guo Y; Cao X
    Eur J Med Chem; 2024 May; 271():116405. PubMed ID: 38678823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of erythrina-based PARP-1/FTase dual-target inhibitors against lung cancer epithelial-mesenchymal transition (EMT) in vivo and in vitro.
    Yu L; Wang YD; Yan ZW; Zhang LY; Li S
    Bioorg Chem; 2024 Jul; 148():107480. PubMed ID: 38772291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Olaparib-Based Photoaffinity Probes for PARP-1 Detection in Living Cells.
    Voorneveld J; Florea BI; Bakkum T; Mendowicz RJ; van der Veer MS; Gagestein B; van Kasteren SI; van der Stelt M; Overkleeft HS; Filippov DV
    Chembiochem; 2020 Sep; 21(17):2431-2434. PubMed ID: 32282108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis and biological evaluation of erythrina derivatives bearing a 1,2,3-triazole moiety as PARP-1 inhibitors.
    Li S; Li XY; Zhang TJ; Zhu J; Xue WH; Qian XH; Meng FH
    Bioorg Chem; 2020 Mar; 96():103575. PubMed ID: 31962202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.
    Wang YQ; Wang PY; Wang YT; Yang GF; Zhang A; Miao ZH
    J Med Chem; 2016 Nov; 59(21):9575-9598. PubMed ID: 27416328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis and evaluation of potential inhibitors for poly(ADP-ribose) polymerase members 1 and 14.
    Kam CM; Tauber AL; Levonis SM; Schweiker SS
    Future Med Chem; 2020 Dec; 12(24):2179-2190. PubMed ID: 33225736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors.
    Passeri D; Camaioni E; Liscio P; Sabbatini P; Ferri M; Carotti A; Giacchè N; Pellicciari R; Gioiello A; Macchiarulo A
    ChemMedChem; 2016 Jun; 11(12):1219-26. PubMed ID: 26424664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BTH-8, a novel poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, causes DNA double-strand breaks and exhibits anticancer activities in vitro and in vivo.
    Guo C; Zhang F; Wu X; Yu X; Wu X; Shi D; Wang L
    Int J Biol Macromol; 2020 May; 150():238-245. PubMed ID: 32057845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-based design of new poly (ADP-ribose) polymerase (PARP-1) inhibitors.
    Chadha N; Jaggi AS; Silakari O
    Mol Divers; 2017 Aug; 21(3):655-660. PubMed ID: 28653128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of the PARP (poly ADP-ribose polymerase) inhibitor 2-(1-(4,4-difluorocyclohexyl)piperidin-4-yl)-1H-benzo[d]imidazole-4-carboxamide for the treatment of cancer.
    Tang L; Wu W; Zhang C; Shi Z; Chen D; Zhai X; Jiang Y
    Bioorg Chem; 2021 Sep; 114():105026. PubMed ID: 34186467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery and SAR study of 2-(1-propylpiperidin-4-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) for the treatment of cancer.
    Zhu Q; Wang X; Hu Y; He X; Gong G; Xu Y
    Bioorg Med Chem; 2015 Oct; 23(20):6551-9. PubMed ID: 26422786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contrasting sirtuin and poly(ADP-ribose)polymerase activities of selected 2,4,6-trisubstituted benzimidazoles.
    Yeong KY; Tan SC; Mai CW; Leong CO; Chung FF; Lee YK; Chee CF; Abdul Rahman N
    Chem Biol Drug Des; 2018 Jan; 91(1):213-219. PubMed ID: 28719017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of 2-(1-(3-(4-Chloroxyphenyl)-3-oxo- propyl)pyrrolidine-3-yl)-1
    Min R; Wu W; Wang M; Tang L; Chen D; Zhao H; Zhang C; Jiang Y
    Molecules; 2019 May; 24(10):. PubMed ID: 31108884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.
    Wang B; Chu D; Feng Y; Shen Y; Aoyagi-Scharber M; Post LE
    J Med Chem; 2016 Jan; 59(1):335-57. PubMed ID: 26652717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.